Vivani Medical

VANI

Market cap $71.7M

Overview Fund Activity

1.21 USD

+0.01

0.83%

At close Updated Sep 12, 4:00 PM EDT

1 day

0.83%

5 days

-9.02%

1 month

-4.72%

3 months

1.68%

6 months

16.35%

Year to date

0.83%

1 year

-2.42%

5 years

-48.95%

10 years

-99.49%

About: Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.

Employees: 36

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

7% more funds holding

Funds holding: 28 [Q1] → 30 (+2) [Q2]

5% more capital invested

Capital invested by funds: $4.99M [Q1] → $5.23M (+$233K) [Q2]

0% more call options, than puts

Call options by funds: $2K | Put options by funds: $2K

1.19% less ownership

Funds ownership: 8.03% [Q1] → 6.84% (-1.19%) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4

231% upside

Avg. target

$4

231% upside

High target

$4

231% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Yi Chen

$4

Buy

Reiterated

2 Sep 2025

See Analyst Rankings

Financial journalist opinion

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing novel, ultra long-acting drug implants, today announced plans to initiate a Phase 1 clinical study in the NPM-139 semaglutide implant program in the first half of 2026, pending regulatory clearance.

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York.

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

Zacks Investment Research

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.

I Missed The Quantum Rally - I Won't Miss The Next One

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025.

Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vivani Medical Announces $8.25M Private Placement Equity Financing

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a private placement.

Vivani Medical Announces $8.25M Private Placement Equity Financing

See News Rankings

Charts implemented using Lightweight Charts™